Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study
Antoine Vasseur,
Matthieu Carton,
Severine Guiu,
Paule Augereau,
Lionel Uwer,
Marie-Ange Mouret-Reynier,
Christelle Levy,
Jean-Christophe Eymard,
Jean-Marc Ferrero,
Marianne Leheurteur,
Anthony Goncalves,
Marie Robert,
Thibault De La Motte Rouge,
Thomas Bachelot,
Thierry Petit,
Marc Debled,
Thomas Grinda,
Isabelle Desmoulins,
Laurence Vanlemmens,
Vincent Nicolaï,
Gaëtane Simon,
Luc Cabel
Affiliations
Antoine Vasseur
Department of Medical Oncology, Institut Curie, 26 Rue d’Ulm, 75005, Paris & Saint-Cloud, France
Matthieu Carton
Department of Biostatistics, Institut Curie, 26 Rue d’Ulm, 75005, Paris & Saint-Cloud, France
Severine Guiu
Department of Medical Oncology, Institut du Cancer de Montpellier, 208 Rue des Apothicaires, 34298, Montpellier, France
Paule Augereau
Department of Medical Oncology, Institut de Cancérologie de l’Ouest Nantes & Angers, Boulevard Professeur Jacques Monod, 44800, Saint-Herblain, France
Lionel Uwer
Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519, Vandœuvre-lès-Nancy, France
Marie-Ange Mouret-Reynier
Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011, Clermont Ferrand, France
Christelle Levy
Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000, Caen, France
Jean-Christophe Eymard
Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue du Général Koenig, 51100, Reims, France
Jean-Marc Ferrero
Department of Medical Oncology, Centre Antoine Lacassagne, 33, avenue de Valombrose, 06100, Nice, France
Marianne Leheurteur
Department of Medical Oncology, Centre Henri Becquerel, Rue d’Amiens, 76000, Rouen, France
Anthony Goncalves
Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France
Marie Robert
Department of Medical Oncology, Institut de Cancérologie de l’Ouest Nantes & Angers, 15 rue André Boquel, 49055, Angers, France
Thibault De La Motte Rouge
Department of Medical Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000, Rennes, France
Thomas Bachelot
Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon, France
Thierry Petit
Department of Medical Oncology, Centre Paul Strauss, 3 Rue de la Porte de l'Hôpital, 67000, Strasbourg, France
Marc Debled
Department of Medical Oncology, Institut Bergonié, Cours de l’Argonne, 33000, Bordeaux, France
Thomas Grinda
Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
Isabelle Desmoulins
Department of Medical Oncology, Centre Georges-François Leclerc, 1 rue Professeur Marion, 21000, Dijon, France
Laurence Vanlemmens
Department of Medical Oncology, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000, Lille, France
Vincent Nicolaï
Department of Medical Oncology, Institut Claudius Regaud – IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059, Toulouse, France
Gaëtane Simon
Department of Real World Data, Data Office of Unicancer, 101 rue de Tolbiac, 75013, Paris, France
Luc Cabel
Department of Medical Oncology, Institut Curie, 26 Rue d’Ulm, 75005, Paris & Saint-Cloud, France; Corresponding author. Department of Medical Oncology, Institut Curie, 26 Rue d’Ulm, 75005, Paris, France.
Background: Taxanes are one of the most effective chemotherapies (CT) in breast cancer (BC), but the efficacy of taxanes rechallenge in early metastatic relapse has been poorly studied in patients previously treated by taxanes in the (neo)adjuvant setting. Our study aimed to analyse the efficacy of taxane rechallenge in case of early metastatic relapse in a multicentre retrospective observational study compared with other chemotherapies. Methods: We analysed the French national ESME metastatic BC (MBC) database and selected HER2- MBC patients who received CT in first-line treatment for a metastatic relapse occurring 3–24 months after previous (neo)adjuvant taxanes treatment. Results: Of 23,501 female patients with MBC in ESME, 1057 met the selection criteria. 58.4% received a taxane-based regimen (75.4% concomitant bevacizumab) and 41.6% received other CT.In hormone-receptor positive (HR+)/HER2- MBC, multivariate analysis showed no difference in OS between taxanes without bevacizumab compared to other CT (HZR = 1.3 [0.97; 1.74], but taxanes was significantly associated with worse PFS (HZR = 1.48 [1.14; 1.93]).In TNBC, taxanes without bevacizumab and carboplatin/gemcitabine were not superior to other CT for OS (HZR = 1.07 [0.79; 1.44] and HZR = 0.81 [0.58; 1.13], respectively), while for PFS, taxanes was inferior (HZR = 1.33 [1.06–1.67]) and carboplatin plus gemcitabine was superior to other CT (HZR = 0.63 [0.46; 0.87]).For both subtypes, the worse outcome observed with paclitaxel was no longer observed with the addition of bevacizumab. Conclusions: With the limitation of retrospective design, taxanes rechallenge in early metastatic relapse of BC may result in a worse PFS in TNBC and HR+/HER2- MBC, which was not observed with the addition of bevacizumab.
